https://feeds.newsfilecorp.com/company/10298 Latest news from DMK Pharmaceuticals, as distributed by TMX Newsfile. en CopyRight (c) 2026, Newsfile Corp. All Rights Reserved. office@newsfilecorp.com (Newsfile Corp.) office@newsfilecorp.com (Newsfile Corp.) Wed, 11 Mar 2026 01:12:03 -0400 https://www.newsfilecorp.com/images/newswire/customer-logos/10298.jpg https://feeds.newsfilecorp.com/company/10298 https://www.newsfilecorp.com/release/196763/DMK-Pharmaceuticals-Commences-Restructuring-Proceeding San Diego, California--(Newsfile Corp. - February 2, 2024) - DMK Pharmaceuticals Corporation (NASDAQ: DMK) ("DMK" or the "Company"), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders, and certain of its direct and indirect subsidiaries (collectively, the "Company Parties") today (the "Petition Date") commenced bankruptcy cases (the "Chapter 11 Cases") by filing voluntary petitions...<img src="https://api.newsfilecorp.com/newsinfo/196763/156" id="156" width="2" height="2" style="width: 1px; height: 1px;border: 0px solid;" /> Fri, 02 Feb 2024 20:28:00 -0500 en https://www.newsfilecorp.com/release/196763